The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/182552

Please be advised that this information was generated on 2020-02-14 and may be subject to change.
EXTENDED REPORT

GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes

Akiyoshi Nakayama,1 Hirofumi Nakaoka,2 Ken Yamamoto,3 Masayuki Sakiyama,1,4 Amara Shaukat,5 Yu Toyoda,6 Yukinori Okada,7,8,9 Yoichiro Kamatani,8 Takahiro Nakamura,10 Tappei Takada,6 Katsuhsna Inoue,11 Tomoya Yasuji,s,12 Hiroaki Yuasa,12 Yuko Shirahama,3 Hiroshi Nakashima,13 Seiko Shimizu,1 Toshihide Higashino,1 Yusuke Kawamura,1 Hiraku Ogata,1 Makoto Kawaguchi,1 Yasuyuki Ohkawa,14 Inaho Danjo,15 Atsumi Tokumasu,16 Keiko Ooyama,16 Toshimitsu Ito,17 Takaaki Kondo,18 Kenji Wakai,19 Blanka Stiburkova,20,21 Karel Pavelka,21 Lisa K Stamp,22 Nicola Dalbeth,23 Eurogout Consortium Yutaka Sakurai,13 Hiroshi Suzuki,6 Makoto Hosoyama,24 Shin Fujimori,25 Takashi Yokoo,26 Tatsuo Hosoya,26,27 Ituro Inoue,2 Atsushi Takahashi,8,28 Michiaki Kubo,29 Hiroshi Ooyama,16 Toru Shimizu,30,31 Kimiyoshi Ichida,27,32 Nariyoshi Shinomiya,1 Tony R Merriman,5 Hirotaka Matsuo1

ABSTRACT

Objective A genome-wide association study (GWAS) of gout and its subtypes was performed to identify novel gout loci, including those that are subtype-specific.

Methods Putative causal association signals from a GWAS of 945 clinically defined gout cases and 1213 controls from Japanese males were replicated with 1396 cases and 1268 controls using a custom chip of 1961 single nucleotide polymorphisms (SNPs). We also first conducted GWASs of gout subtypes. Replication with Caucasian and New Zealand Polynesian samples was done to further validate the loci identified in this study.

Results In addition to the five loci we reported previously, further susceptibility loci were identified at a genome-wide significance level ($p<5.0\times10^{-8}$): urate transporter genes (SLC22A12 and SLC17A1) and HISTH2BF-HISTH4E for all gout cases, and NIPAL1 and FAM35A for the renal underexcretion gout subtype. While NIPAL1 encodes a magnesium transporter, functional analysis did not detect urate transport via NIPAL1, suggesting an indirect association with urate handling. Localisation analysis in the human kidney revealed expression of NIPAL1 and FAM35A mainly in the distal tubules, which suggests the involvement of the distal nephron in urate handling in humans. Clinically ascertained male patients with gout and controls of Caucasian and Polynesian ancestries were also genotyped, and FAM35A was associated with gout in all cases. A meta-analysis of the three populations revealed FAM35A to be associated with gout at a genome-wide level of significance ($p_{\text{meta}}=3.58\times10^{-8}$).

Conclusions Our findings including novel gout risk loci provide further understanding of the molecular pathogenesis of gout and lead to a novel concept for the therapeutic target of gout/hyperuricaemia.

INTRODUCTION

Gout is a common disease characterised by acute painful arthritis, and its global burden continues to rise with the increasingly ageing population.1 Gout is caused by hyperuricaemia, and can be classified according to patients’ clinical parameters reflecting its causes2,3 as renal overload (ROL) gout and renal underexcretion (RUE) gout. As shown in online supplementary figure S1, patients with gout with increased urinary excretion of urate due to overproduction and/or decreased extra-renal underexcretion of urate are classified as having ROL gout, whereas those with decreased renal excretion of urate are defined as having RUE gout.2 Reflecting their causes, almost all patients with gout are divided into those two subtypes. Although these subtypes are important from both genetic and pathophysiological points of view,2,4 genome-wide association studies (GWASs) of gout subtypes have never been performed, partly due to the difficulty in assembling sufficient gout cases with requisite clinical data, including data from a time-consuming urinary collection examination.

We and other groups5–9 recently reported gout/hyperuricaemia to have relatively strong genetic risk factors. More recently, and for the first time, we performed a GWAS with only clinically defined Japanese male gout cases in which 16 single nucleotide polymorphisms (SNPs) were replicated, and five gout-risk loci were identified including two novel loci (MYL2-CUX2 and CNIH-2).10 In the present study (see online supplementary figure S2), we extended our analysis to identify novel susceptibility loci for gout by replicating approximately 2000 SNPs top-ranked in the GWASs of all gout and/or its subtypes. In addition, for the first time, we performed GWASs of gout subtypes to identify...
subgroup-specific (cause-specific) risk loci. Furthermore, we conducted a replication study with independent Caucasian and Polynesian populations to validate loci.

**METHODS**

**Subjects and genotyping**

Genome-wide genotyping was performed with the Illumina HumanOmniExpress-12 v1.0 (Illumina) platform using 946 clinically defined gout cases and 1213 controls, all Japanese males. Detailed methods of genotyping and quality control are previously described. Ultimately, 570 442 SNPs passed filters for 945 cases and 1213 controls. At the replication stage, 1246 cases were genotyped with a custom genotyope platform using iSelect HD Custom Genotyping BeadChips (Illumina) on 1961 SNPs, as described in online supplementary methods and supplementary figure S3, and 150 gout cases were genotyped with the Illumina HumanOmniExpress-24 v1.0 (Illumina) platform. For controls, 1268 Japanese males with a serum uric acid (SUA) level ≤ 7.0 mg/dL and without gout history were recruited from BioBank Japan11 12 and genotyped with the Illumina HumanOmniExpress-12 v1.0 (Illumina) platform. Finally, 1961 SNPs with 1396 gout cases and 1268 controls were successfully genotyped (see online supplementary table S1). A genome-wide significance threshold was set to be \(\alpha=5.0 \times 10^{-8}\) to claim evidence of a significant association.

GWASs of the two subtypes of gout, ROL gout and RUE gout (see online supplementary figure S1), were also performed, followed by replication studies with a custom SNP chip (see online supplementary figure S3) and a subsequent meta-analysis. As described previously,2 10 and shown in online supplementary figure S1 and supplementary methods, ROL gout and RUE gout are defined when patients’ urinary urate excretion is over 25.0 mg/hour/1.73 m² (600 mg/day/1.73 m²) and patients’ urate clearance (urate clearance/creatinine clearance ratio, FEUA) is under 5.5%, respectively. For GWASs of gout subtypes, 1178 cases were classified as ROL gout (560 cases at GWAS stage and 618 cases at replication stage) and 1315 cases as RUE gout (619 cases at GWAS stage and 696 cases at replication stage), respectively (see online supplementary table S2).

A replication study with independent Caucasian and New Zealand (NZ) Polynesian sample sets was also performed to validate the genetic risk loci identified in the present study. This replication was done in a data set recruited from New Zealand13 and from Europe by the Eurogout Consortium14 comprising 1319 male cases and 514 male controls of European ancestry and 971 male cases and 565 male controls of NZ Polynesian ancestry. SNPs were genotyped by an allelic discrimination assay (TaqMan) with a LightCycler 480 Real-Time PCR (RT-PCR) System (Roche Applied Science, Indianapolis, Indiana, USA). Detailed information of clinical characteristics and genetic analysis is shown in online supplementary methods and tables S1-S3.

**Statistical analyses**

The inverse-variance fixed-effects model was used for meta-analysis. In the meta-analysis with Japanese, Caucasian and NZ Polynesian populations or in the presence of heterogeneity \((p_{het} < 0.05 \text{ or } I^2 > 50\%)\), we implemented the DerSimonian and Laird random-effects model for meta-analysis. For the replication analysis with Caucasian and NZ Polynesian sample sets, ORs were adjusted by age and ancestral group. All the meta-analyses were performed using the R V.3.1.1 and 3.2.2 (R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2006) with meta package. All calculations of linkage disequilibrium (LD, measured in \(r^2\)) were conducted using the Japanese population. The detailed information for statistical analyses is described in online supplementary methods.

**Functional and localisation analyses**

Urate transport analysis of NIPAL1 was performed with an oocyte expression system16 17 with high potassium (HK) buffer or HK buffer without magnesium. For immunohistochemical analysis, the human kidney sections (3 μm) incubated with anti-human NIPAL1 antibody (1:50) (LS-C164878; Sigma-Aldrich, Missouri, USA) were used, and then visualised with diamobenzidine (0.8 mM).18 19 Intracellular localisation of NIPAL1 was also studied in Xenopus oocytes and Madin-Darby canine kidney II (MDCKII) cells. Detailed information for the functional and localisation analyses is described in online supplementary methods.

**RESULTS**

**GWAS of all gout and its subtypes**

In addition to the GWAS stage previously performed with 945 patients with clinically defined gout and 1213 controls, all Japanese males10 (see online supplementary figure S4), the replication stage for all cases of gout was carried out by genotyping 1961 SNPs (see online supplementary figure S3 and supplementary note) in a further 1396 male patients and 1268 male controls, and a meta-analysis then conducted (see online supplementary figure S2). Furthermore, GWASs of two subtypes of gout, ROL gout (figure 1A) and RUE gout (figure 1B), were also performed in the present study, followed by replication studies with a custom SNP chip and a subsequent meta-analysis.

**Meta-analysis**

Downloaded from http://ard.bmj.com/ on September 12, 2019 at Radboud University Nijmegen.
For GWASs of gout subtypes, 1178 cases were classified as ROL gout (560 cases at GWAS stage and 618 cases at replication stage) and 1315 cases as RUE gout (619 cases at GWAS stage and 696 cases at replication stage), respectively. GWAS, genome-wide association study; ROL, renal overload; RUE, renal underexcretion.

Figure 1 Manhatten plots of GWASs of subtypes of gout. Manhatten plots of GWASs of (A) ROL gout subtype and (B) RUE gout subtype. X-axis shows chromosomal positions. Y-axis shows $-\log_{10}$ p values. The upper and lower dotted lines indicate the genome-wide significance threshold ($p=5.0 \times 10^{-8}$) and the cut-off level for selecting single nucleotide polymorphisms for replication study ($p=0.001$), respectively. GWAS, genome-wide association study; ROL, renal overload; RUE, renal underexcretion.

Urate transport analysis of NIPAL1 transporter
NIPAL1 and FAM35A were revealed to be associated with RUE gout in the present study. NIPAL1 has been reported to be a magnesium transporter, which has nine transmembrane domains (figure 3A), whereas FAM35A is predicted to be a soluble protein. In this context, we hypothesised that NIPAL1 could be involved in the regulation of urate handling as a renal urate efflux transporter. However, our functional analysis using Xenopus oocytes did not show urate transport via NIPAL1, regardless of the presence of magnesium (figure 3B).

Localisation analysis of NIPAL1 and FAM35A
By immunohistochemical analysis, NIPAL1 and FAM35A showed cytosolic expression in the renal distal tubules of human kidney (figure 4A, B). Both proteins were also weakly detected in the cytoplasm of collecting ducts. NIPAL1-expressing Xenopus oocytes and MDCKII cells also showed intracellular localisation of NIPAL1 (see online supplementary figure S6).

Replication study of all gout cases with Caucasian and Polynesian populations
A replication study for the discovered loci (SLC22A12, SLC17A1, HIST1H2BF-HIST1H4E, NIPAL1 and FAM35A) was performed for all gout cases with males drawn from Caucasian (1319 cases and 514 controls) and NZ Polynesian populations (971 cases and 565 controls). Because a gain-of-function SNP of SLC17A1, rs1165196 (Ile269Thr), was in strong LD with SLC17A1 (rs1165176 (r$^2=0.99$), we performed the following analyses using rs1165196, assuming that the causal SNP in this locus was rs1165196 of SLC17A1. Among these five loci, the
<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP* Chr.</th>
<th>Replication study**</th>
<th>Meta-analysis</th>
<th>Heterogeneity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Frequency of A1</td>
<td></td>
<td></td>
<td>Frequency of A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OR (95% CI) p Value</td>
<td></td>
<td></td>
<td>OR (95% CI) p Value</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OR (95% CI) p Value</td>
<td></td>
<td></td>
<td>OR (95% CI) p Value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCKR</td>
<td>rs1260326 2 27730940</td>
<td>0.616 0.535 1.39 (1.23 to 1.57) 134x10⁻⁷</td>
<td>0.611 0.557 1.25 (1.15 to 1.36) 7.19x10⁻¹⁰</td>
<td>0.20 38.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs11733284 4 48028097</td>
<td>0.346 0.271 1.35 (1.17 to 1.55) 6.48x10⁻⁷</td>
<td>0.324 0.250 1.34 (1.16 to 1.54) 3.68x10⁻⁷</td>
<td>0.20 47.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs2728104 4 88973006</td>
<td>0.738 0.633 1.63 (1.40 to 1.92) 1.58x10⁻⁷</td>
<td>0.720 0.613 1.57 (1.40 to 1.77) 4.58x10⁻⁷</td>
<td>0.30 48.1</td>
<td></td>
</tr>
<tr>
<td>SLC2A9</td>
<td>rs3733589 4 9987324</td>
<td>0.662 0.570 1.48 (1.28 to 1.71) 2.00x10⁻⁷</td>
<td>0.658 0.568 1.47 (1.26 to 1.68) 2.05x10⁻⁷</td>
<td>0.34 30.3</td>
<td></td>
</tr>
<tr>
<td>ABCG2</td>
<td>rs1871744 4 89039629</td>
<td>0.834 0.723 1.93 (1.62 to 2.29) 3.85x10⁻⁷</td>
<td>0.828 0.712 1.84 (1.56 to 2.15) 4.32x10⁻⁷</td>
<td>0.17 20.4</td>
<td></td>
</tr>
<tr>
<td>FAM35A</td>
<td>rs7903456 10 88919319</td>
<td>0.303 0.248 1.32 (1.13 to 1.53) 4.32x10⁻⁷</td>
<td>0.293 0.240 1.32 (1.13 to 1.50) 4.32x10⁻⁷</td>
<td>0.29 20.4</td>
<td></td>
</tr>
</tbody>
</table>

**SNP* dbSNP rs number. SNPs having associations for all gout, ROL gout and RUE gout at the lowest p value in each locus by meta-analysis are shown in this table.

**SNP positions are based on NCBI human genome reference sequence build 37.

OR, odds ratio; CI, confidence interval; p, p value; Chr., chromosome; GWAS, genome-wide association study; ROL, renal overload; RUE, renal underexcretion; SNP, single nucleotide polymorphism.
Figure 2  Regional association plots of five discovered loci. Three loci were revealed to exceed the genome-wide significance level from the meta-analysis with all gout cases, and two loci with renal underexcretion (RUE) gout cases. The highest association signal in each panel is located on (A) SLC22A12, (B) SLC17A1 and (C) HIST1H2BF-HIST1H4E for all gout cases, and (D) NIPAL1 and (E) FAM35A for RUE gout cases. The region within 250 kb from the single nucleotide polymorphism (SNP) indicating the lowest p value is shown. (Top panel) Plots of $-\log_{10}$ p values for the test of SNP association with gout in the genome-wide association study stage. The SNP showing the lowest p value in the meta-analysis is depicted as a pink diamond. Other SNPs are colour-coded according to the extent of linkage disequilibrium (measured in $r^2$) with the SNP showing the lowest p value. (Middle panel) Recombination rates (centimorgans per Mb) estimated from HapMap Phase II data are plotted. (Bottom panel) RefSeq genes. Genomic coordinates are based on NCBI human genome reference sequence build 37.

Figure 3  Functional analysis of NIPAL1 transporter. (A) The topological model of the NIPAL1 transporter. NIPAL1 is predicted to have nine transmembrane regions. The amino acid sequences of NIPAL1 were obtained from GenBank (accession code NM_207330). (B) Urate transport analysis of NIPAL1. SLC2A9 (also known as GLUT9) is a renal urate transporter and is used for a positive control for the urate transport analysis. In contrast to SLC2A9, urate transport via NIPAL1 was not detected, regardless of the presence of magnesium. Data are expressed as mean±SEM (n=8). Statistical analyses for significant differences were performed according to Student’s t-test. (**p<0.01; N.S., not significantly different as compared with control.).
meta-analysis of those populations for all gout revealed a significant association with rs7903456 of FAM35A ($p_{meta}=9.72\times10^{-3}$; OR=1.17) (table 2). Although SLC17A1 did not show significance ($p_{meta}=0.119$) in the present study of those populations (table 2), a previous paper revealed a significant association of SLC17A1 with gout in Caucasian and NZ Polynesian sample sets, indicating the necessity of further replication studies to investigate the ancestral differences in the significance of other genetic loci including SLC17A1. Genotyping the CUX2 and CNIH-2 loci, which were identified in both our present and previous GWASs of Japanese, was also performed, and the CUX2 locus was replicated successfully for the first time in other populations (see online supplementary table S5). The results of further association analyses and expression quantitative trait locus (eQTL) analysis are shown in online supplementary note and tables S6 and S7. Significant effects on FEUA were detected in NIPAL1, FAM35A and SLC22A12 loci in the Japanese population, and were also observed at SLC17A1 in NZ Polynesian population.

A further meta-analysis of all gout cases with Japanese, Caucasian and NZ Polynesian populations was performed for NIPAL1 and FAM35A, which were at a genome-wide significance level in the Japanese population only for the RUE gout subtype, and not for all gout cases. rs11733284 of NIPAL1 was not associated with all gout ($p_{meta}=0.16$; OR=1.11), suggesting the presence of ancestral differences in genetic effects of this locus, or a subtype-specific effect. On the other hand, rs7903456 of FAM35A showed an association with all gout at a genome-wide level of significance ($p_{meta}=3.58\times10^{-8}$; OR=1.23) (figure 5), indicating that rs7903456 is a susceptibility locus for all gout as well as the RUE gout subtype.

Table 2: Replication study of all gout for five discovered loci in Caucasian and NZ Polynesian sample sets

<table>
<thead>
<tr>
<th>SNP*</th>
<th>Chr.</th>
<th>Position (bp)</th>
<th>Gene</th>
<th>rs SNP</th>
<th>A1/A2</th>
<th>Caucasian Cases</th>
<th>Controls</th>
<th>OR (95% CI)</th>
<th>p Value</th>
<th>NZ Polynesian Cases</th>
<th>Controls</th>
<th>OR (95% CI)</th>
<th>p Value</th>
<th>Meta-analysis** OR (95% CI) p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs11733284</td>
<td>4</td>
<td>48083897</td>
<td>NIPAL1</td>
<td>A</td>
<td>G</td>
<td>0.362</td>
<td>0.356</td>
<td>1.01 (0.86 to 1.18)</td>
<td>0.896</td>
<td>0.251</td>
<td>0.270</td>
<td>0.92 (0.77 to 1.09)</td>
<td>0.603</td>
<td>0.355</td>
</tr>
<tr>
<td>rs1165196</td>
<td>6</td>
<td>25813150</td>
<td>SLC17A1</td>
<td>T</td>
<td>C</td>
<td>0.614</td>
<td>0.583</td>
<td>1.11 (0.95 to 1.30)</td>
<td>0.271</td>
<td>0.231</td>
<td>0.271</td>
<td>1.12 (0.93 to 1.33)</td>
<td>0.192</td>
<td>0.711</td>
</tr>
<tr>
<td>rs11758351</td>
<td>6</td>
<td>26203910</td>
<td>HIST1H2BF-HIST1H4E</td>
<td>G</td>
<td>T</td>
<td>0.141</td>
<td>0.158</td>
<td>0.86 (0.70 to 1.07)</td>
<td>0.173</td>
<td>0.199</td>
<td>0.199</td>
<td>0.90 (0.74 to 1.09)</td>
<td>0.334</td>
<td>0.88 (0.77 to 1.02)</td>
</tr>
<tr>
<td>rs7903456</td>
<td>10</td>
<td>88919396</td>
<td>FAM35A</td>
<td>A</td>
<td>G</td>
<td>0.737</td>
<td>0.699</td>
<td>1.18 (1.00 to 1.38)</td>
<td>0.0462</td>
<td>0.351</td>
<td>0.333</td>
<td>1.16 (0.98 to 1.38)</td>
<td>0.0997</td>
<td>1.17 (1.04 to 1.32)</td>
</tr>
<tr>
<td>rs2285340</td>
<td>11</td>
<td>64435906</td>
<td>SLC22A12</td>
<td>A</td>
<td>G</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

*dbSNP rs number.
†SNP positions are based on NCBI human genome reference sequence build 37.4.
‡A1 is risk-associated allele, and A2 is non-risk-associated allele.
§1319 cases for all gout and 514 controls from Caucasian male population.
¶971 cases for all gout and 565 controls from NZ Polynesian male population.
**Meta-analysis of Caucasian and NZ Polynesian samples.
††rs2285340 is monomorphic in Caucasians.
Meta-analysis of all gout for the other three loci (SLC22A12, SLC17A1 and HIST1H2BF-HIST1H4E) was also performed with Japanese, Caucasian and NZ Polynesian populations as shown in online supplementary figure S7. rs11758351 of HIST1H2BF-HIST1H4E did not show a significant association with gout (p-meta=0.40; OR=1.12). rs2285340 of SLC22A12 and rs1165196 of SLC17A1 did not reach a genome-wide level of significance (p-meta=2.47×10^{-4}; OR=1.31; and p-meta=1.28×10^{-3}; OR=1.25, respectively) partly due to statistical fluctuation in relatively small sample sets, although the effects were consistently in the same direction.

DISCUSSION

With clinically defined gout cases, we previously performed a GWAS and revealed that ABCG2, SLC2A9, MYL2-CUX2, GCKR and CNH-2 were associated with gout at a genome-wide significance level (see online supplementary figure S4). A more recent GWAS by Li et al^18^ with clinically ascertained gout cases revealed three novel loci (BCAS3, RFX3 and KCNJ11) in Han Chinese. In the present study, we performed a gout follow-up study focused on loci not reaching the genome-wide level of significance in the previous GWAS,^10^ genotyping 1961 SNPs in an additional 1396 cases and 1268 controls. We revealed a total of 1396 cases and 1268 controls. We revealed a total of eight loci to be associated with all gout cases in Japanese males (table 1). Among them, three loci (SLC22A12, SLC17A1 and HIST1H2BF-HIST1H4E) were first identified as gout risk loci at a genome-wide significance level by the present GWAS approach.

Both SLC22A12 and SLC17A1 encode urate transporters at the apical side of the renal proximal tubule^16^ (see online supplementary figure S8) and are reportedly associated with SUA in humans by previous GWASs of SUA. ^12^ These loci were identified in a genome-wide significance level, showing the importance of these loci for the pathogenesis of both gout subtypes. Especially for RUE gout, three more loci, SLC22A12, NIPAL1 and FAM35A, were identified to be associated at a genome-wide significance level. As described above, it is compatible for SLC22A12 to be associated with RUE gout, because SLC22A12 encodes a renal urate reabsorbtion transporter. ^23^

Of note, NIPAL1 and FAM35A were identified as novel loci by performing GWAS of the RUE gout subtype. Associations with gout and SUA have never been previously reported with NIPAL1 and FAM35A. Furthermore, to our knowledge, there is no study reporting an association between any diseases and NIPAL1 or FAM35A.

NIPAL1, also known as NIPA3, is reportedly expressed on the membrane of some organs including kidney, and to be a magnesium transporter. ^24^ As another magnesium transporter NIPA2, NIPA2 is associated with RUE gout (ie, gout with renal urate underexcretion), we hypothesised that NIPAL1 is a urate transporter in the human kidney. However, our functional study did not show urate transport via NIPAL1, regardless of the presence of magnesium (figure 3B). Moreover, localisation to the membrane was not detected for NIPAL1 protein, which was mainly expressed within the distal tubules of human kidney, as revealed by immunohistochemical analysis (figure 4A). A similar result was obtained in confocal microscopic observation, with NIPAL1-expressing oocytes showing intracellular localisation of NIPAL1 protein (see online supplementary figure S6). These findings suggest that NIPAL1 is not a urate transporter and that it might be involved in the indirect regulation of urate transport kinetics. Nevertheless, recent studies have revealed associations between hyperuricaemia and magnesium intake,^29^ serum magnesium level^30^ and magnesium excretion. ^31^ Together with previous reports, our findings support the hypothesis that there could be some relationship between gout and magnesium handling via magnesium transporters including NIPAL1, and that the present study could well provide new insights into the genetic background of urate and magnesium handling in patients with gout/hyperuricaemia.

FAM35A is ubiquitously expressed in organs including the kidney, and our immunohistochemical analysis of human kidney also revealed cytosolic immunoreactivity of the FAM35A protein mainly in the distal tubules (figure 4B). Our findings from FAM35A and NIPAL1 suggest the involvement of the distal nephrone in gout progression as well as dysfunction in urate handling in humans (see online supplementary figure S8). To date, the molecular function of FAM35A is totally unknown. Although further studies are necessary to confirm this, it is possible that genes near FAM35A including GLUD1 (figure 2E)
have some relationship with gout (see also online supplementary note for details).

In addition to studying the Japanese population, we performed a replication study with male Caucasian and NZ Polynesian sample sets for the five newly discovered loci. Since they were not divided into subtypes, further evaluations by meta-analysis were conducted with all gout groups. While other loci were not replicated, rs7903456 of FAM35A was replicated with a significant association with gout (table 2). CUX2, which was reported by both our present and previous gout GWAS in Japanese, was also replicated in these sample sets (see online supplementary table S5).

A meta-analysis of all gout with Japanese, Caucasian and NZ Polynesian populations for these five SNPs revealed FAM35A to be associated with all gout at the genome-wide significance level (figure 5B), and that rs2285340 of SLC22A12 and rs1165196 of SLC17A1 showed a significant association but did not reach a genome-wide significance level (see online supplementary figure S7). rs11758351 of HIST1H2BF-HIST1H4E and rs11733284 of NIPAL1 were not associated by this meta-analysis, although these loci showed a genome-wide significant association in the Japanese population. Since this might be due to the differences in LD structure among these populations, a replication analysis with East Asian populations will be necessary for these loci.

Supplementary note for details).

rs2285340 of SLC22A12 was monomorphic (only G allele) in Caucasians and not associated with NZ Polynesians. Therefore, replication studies of this locus in East Asian populations would also be insightful for future analysis. Although the underlying molecular mechanism of gout by FAM35A is unknown, this locus seems to have a common pathophysiological risk of gout for Japanese, NZ Polynesians and Caucasians.

In summary, we performed GWAS of all gout as well as gout subtypes and identified five loci in addition to the five loci that we reported previously. Furthermore, the FAM35A locus showed an association with all gout by meta-analysis among the Japanese, Caucasian and NZ Polynesian sample sets at a genome-wide level of significance. Together with their expression in the renal distal tubules, the identification of NIPAL1 and FAM35A as gout loci suggests the involvement of the distal nephron (see online supplementary figure S9) in the urate handling of the human kidney and in the pathogenesis of gout/hyperuricaemia. These findings could well provide a clue leading to a novel concept for the therapeutic target of gout (see online supplementary figure S10).

Author affiliations

1Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Saitama, Japan
2Division of Transciptomics, Research Center for Transciomics Medicine, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
3Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan
4Ryugokaku East Gate Clinic, Tokyo, Japan
5Department of Internal Medicine, Self-Defense Forces Central Hospital, Tokyo, Japan
6Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
7Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
8First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Institute of Inherited Metabolic Disorders, Prague, Czech Republic
9Institute of Rheumatology, Prague, Czech Republic
10Department of Medicine, University of Otag, Christchurch, New Zealand
11Department of Medicine, University of Auckland, Grafton, Auckland, New Zealand
12Department of Human Physiology and Pathology, Faculty of Pharma-Sciences, Teikyo University, Tokyo, Japan
13Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
14Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
15Department of Pathophysiology and Therapy in Chronic Kidney Disease, Jikei University School of Medicine, Tokyo, Japan
16Komis Research Center, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
17Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Kanagawa, Japan
18Midorigaoka Hospital, Takatsuki, Osaka, Japan
19Kyoto Industrial Health Association, Kyoto, Japan
20Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
21Institute of Rheumatology, Prague, Czech Republic
22Department of Medicine, University of Otago, Dunedin, New Zealand
23Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Saitama, Japan
24Department of Dermatology, National Defense Medical College, Tokorozawa, Saitama, Japan
25Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
26Laboratory for Mathematics, National Defense Medical College, Tokorozawa, Saitama, Japan
27Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
28Omics Research Center, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
29Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Kanagawa, Japan
30Midorigaoka Hospital, Takatsuki, Osaka, Japan
31Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Saitama, Japan
32Laboratory for Mathematics, National Defense Medical College, Tokorozawa, Saitama, Japan
33Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan
34Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Saitama, Japan
35Division of Transciptomics, Research Center for Transciomics Medicine, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
36Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan
37Ryugokaku East Gate Clinic, Tokyo, Japan
38Department of Internal Medicine, Self-Defense Forces Central Hospital, Tokyo, Japan
39Program in Radiological and Medical Laboratory Sciences, Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
40Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
41Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
42First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Institute of Inherited Metabolic Disorders, Prague, Czech Republic
43Institute of Rheumatology, Prague, Czech Republic
44Department of Medicine, University of Otag, Christchurch, New Zealand
45Department of Medicine, University of Auckland, Grafton, Auckland, New Zealand
46Department of Human Physiology and Pathology, Faculty of Pharma-Sciences, Teikyo University, Tokyo, Japan
47Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
48Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
49Department of Pathophysiology and Therapy in Chronic Kidney Disease, Jikei University School of Medicine, Tokyo, Japan
50Komis Research Center, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
51Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Kanagawa, Japan
52Midorigaoka Hospital, Takatsuki, Osaka, Japan
53Kyoto Industrial Health Association, Kyoto, Japan
54Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan

Acknowledgements The authors thank all the participants involved in this study. They are also grateful to members of the BioBank Japan Project for supporting the study. They are indebted to M Watanabe and Y Katsuura (National Defense Medical College) for immunohistochemical analysis; K Gotanda, Y Morimoto, M Miyazawa, T Chiba, Y Utsumi, S Terashige, Y Kato, H Sasaki, Y Takashima, S Tatsukawa, A Akashi, Y Tanahashi, Y Nagao, M Nakajima, H Inoue, S Takeuchi (National Defense Medical College), M Sonoda (Kurume University School of Medicine) and T Tamatsukuri (Jikei University School of Medicine) for genetic analysis; S Ushida (Ikagaku) and H Fujiwara (Midorigaoka Hospital) for Japanese sample collection; R Akuhata, N Aupouri (Ngati Porou Hauora Charitable Trust) and J H Hindmarsh (Research Coordinator, Ngati Porou Hauora Charitable Trust) for NZ Māori (Eastern Polynesian) sample collection from the Rohe (area) of Ngati Porou (Ngati Porou Hauora Charitable Trust) for their biomaterial support and technical advice in the oocyte experiment; J Boocock (University of Otago) for EQTL analysis; H Motohashi (Tohoku University), N Hamajima, M Naito (Ngatō University) and H Tanaka (Aichi Cancer Center Research Institute) for helpful discussion.

Collaborators The authors thank all the participants involved in this study. They are also grateful to members of the BioBank Japan Project for supporting the study. They are indebted to M Watanabe and Y Katsuura (National Defense Medical College) for immunohistochemical analysis; K Gotanda, Y Morimoto, M Miyazawa, T Chiba, Y Utsumi, S Terashige, Y Kato, H Sasaki, Y Takashima, S Tatsukawa, A Akashi, Y Tanahashi, Y Nagao, M Nakajima, H Inoue, S Takeuchi (National Defense Medical College), M Sonoda (Kurume University School of Medicine) and T Tamatsukuri (Jikei University School of Medicine) for genetic analysis; S Ushida (Ikagaku) and H Fujiwara (Midorigaoka Hospital) for Japanese sample collection; R Akuhata, N Aupouri (Ngati Porou Hauora Charitable Trust) and J H Hindmarsh (Research Coordinator, Ngati Porou Hauora Charitable Trust) for NZ Māori (Eastern Polynesian) sample collection from the Rohe (area) of Ngati Porou (Ngati Porou Hauora Charitable Trust) for their biomaterial support and technical advice in the oocyte experiment; J Boocock (University of Otago) for EQTL analysis; H Motohashi (Tohoku University), N Hamajima, M Naito (Ngatō University) and H Tanaka (Aichi Cancer Center Research Institute) for helpful discussion.

Contributors AN, HNakaoka, KY, MS, AY, YT, TS, NR, TRM and HM conceived and designed this study. YSakurai, HS, II, Atakahashia and MKubo assisted with research design. AN, HNakaoka, MS, YKoka, YKamata, THigashino, YKawahara, ATokumasu, KQ, TK, KW, KS, KP, Atakahashia, MKubo, HOoyama, TS, Kichishi and HM collected and analyzed clinical data of Japanese participants. AS, LK, ND, Europout Consortium and TRM collected and analyzed clinical data of replication participants. AN, KY, MS, AYShirahama, SS, THigashino, YKawahara, HOgata, M Kawaguchi, ID, NS, TRM and HM performed genetic analysis. AN, HNakaoka, MS,
This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, including MEXT KAKENHI (Nos. 25293145 and 15K15227). Grants-in-Aid for Scientific Research on Priority Areas (No. 17015018) and Innovative Areas (Nos. 22150001 and 22150002) and a JSPS KAKENHI Grant (Nos. 16H06277 and 16H06279), the Ministry of Health, Labour and Welfare of Japan, the Ministry of Defense of Japan, the Japan Society for the Promotion of Science, the Kawano Masanori Memorial Foundation for Promotion of Pediatrics, the Gout Research Foundation of Japan and the Health Promotion of Pediatrics, the Gout Research Foundation of Japan and the Health Labour and Welfare of Japan, the Ministry of Defense of Japan, the Japan Society for the Promotion of Science, the Kawano Masanori Memorial Foundation for Promotion of Pediatrics, the Gout Research Foundation of Japan and the Health Promotion of Pediatrics, the Gout Research Foundation of Japan and the Health


Clinical and epidemiological research


REFERENCES


